180 related articles for article (PubMed ID: 16478747)
1. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.
Menin C; Scaini MC; De Salvo GL; Biscuola M; Quaggio M; Esposito G; Belluco C; Montagna M; Agata S; D'Andrea E; Nitti D; Amadori A; Bertorelle R
J Natl Cancer Inst; 2006 Feb; 98(4):285-8. PubMed ID: 16478747
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients.
Talseth BA; Meldrum C; Suchy J; Kurzawski G; Lubinski J; Scott RJ
Int J Cancer; 2007 Feb; 120(3):563-5. PubMed ID: 17096342
[TBL] [Abstract][Full Text] [Related]
3. The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
Alhopuro P; Ylisaukko-Oja SK; Koskinen WJ; Bono P; Arola J; Järvinen HJ; Mecklin JP; Atula T; Kontio R; Mäkitie AA; Suominen S; Leivo I; Vahteristo P; Aaltonen LM; Aaltonen LA
J Med Genet; 2005 Sep; 42(9):694-8. PubMed ID: 16141004
[TBL] [Abstract][Full Text] [Related]
4. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome.
Sotamaa K; Liyanarachchi S; Mecklin JP; Järvinen H; Aaltonen LA; Peltomäki P; de la Chapelle A
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6840-4. PubMed ID: 16203772
[TBL] [Abstract][Full Text] [Related]
5. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis.
Ohmiya N; Taguchi A; Mabuchi N; Itoh A; Hirooka Y; Niwa Y; Goto H
J Clin Oncol; 2006 Sep; 24(27):4434-40. PubMed ID: 16983111
[TBL] [Abstract][Full Text] [Related]
6. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
7. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
8. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.
Zhang X; Pageon L; Post SM
Oncogene; 2015 Aug; 34(33):4412-20. PubMed ID: 25435368
[TBL] [Abstract][Full Text] [Related]
10. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells.
Alazzouzi H; Suriano G; Guerra A; Plaja A; Espín E; Armengol M; Alhopuro P; Velho S; Shinomura Y; González-Aguilera JJ; Yamamoto H; Aaltonen LA; Moreno V; Capellà G; Peinado MA; Seruca R; Arango D; Schwartz S
J Med Genet; 2007 Jan; 44(1):75-80. PubMed ID: 16825434
[TBL] [Abstract][Full Text] [Related]
11. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
12. MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.
Hofstetter G; Berger A; Bauer EM; Schuster E; Wolf A; Chamson M; Müller-Holzner E; Reimer D; Braicu EI; Sehouli J; Ulmer H; Cacsire Castillo-Tong D; Zeillinger R; Concin N
Oncol Rep; 2012 Mar; 27(3):673-7. PubMed ID: 22134502
[TBL] [Abstract][Full Text] [Related]
13. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
14. Do CDKN2 p16 540 C>G, CDKN2 p16 580 C>T, and MDM2 SNP309 T>G gene variants act on colorectal cancer development or progression?
Tuna G; Küçükhüseyin O; Arıkan S; Kaytan Sağlam E; Güler E; Cacına C; Oztop O; Turan S; Korkmaz G; Yaylım I
DNA Cell Biol; 2013 Jul; 32(7):400-8. PubMed ID: 23777425
[TBL] [Abstract][Full Text] [Related]
15. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome.
Bougeard G; Baert-Desurmont S; Tournier I; Vasseur S; Martin C; Brugieres L; Chompret A; Bressac-de Paillerets B; Stoppa-Lyonnet D; Bonaiti-Pellie C; Frebourg T
J Med Genet; 2006 Jun; 43(6):531-3. PubMed ID: 16258005
[TBL] [Abstract][Full Text] [Related]
16. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population.
Chaar I; Arfaoui TA; El Amine el HO; Mahmoud LB; Khiari M; Sammoud S; Lounis A; Amara S; Gharbi L; Hmida AB; Mzabi S; Bouraoui S
Eur J Gastroenterol Hepatol; 2012 Mar; 24(3):320-7. PubMed ID: 22266832
[TBL] [Abstract][Full Text] [Related]
17. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.
Ruijs MW; Schmidt MK; Nevanlinna H; Tommiska J; Aittomäki K; Pruntel R; Verhoef S; Van't Veer LJ
Eur J Hum Genet; 2007 Jan; 15(1):110-4. PubMed ID: 17003841
[TBL] [Abstract][Full Text] [Related]
18. MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis.
Cao X; Zhang T; Zhao Z; Zhao T
DNA Cell Biol; 2012 Mar; 31(3):355-9. PubMed ID: 21770737
[TBL] [Abstract][Full Text] [Related]
19. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population.
Chaar I; Amara S; Khiari M; Ounissi D; Dhraif M; Ben Hamida AE; Gharbi L; Mzabi S; Bouraoui S
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):228-36. PubMed ID: 22914606
[TBL] [Abstract][Full Text] [Related]
20. Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.
Hitzenbichler F; Stoehr CG; Rogenhofer M; Wieland WF; Ruemmele P; Hartmann A; Stoehr R
Pathobiology; 2014; 81(2):53-9. PubMed ID: 24217660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
